GlassScriptPhysician profile
Srinadh Annangi
NPI 1427463462
$5,239.86
in general payments reported to CMS, 2019-2025
9 companies · $3,843 in 2025
The $3,843 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $146 · 2021: $392 · 2022: $530 · 2023: $315 · 2024: $13.89 · 2025: $3,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,517 · Travel and Lodging: $1,104 · Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,517.38 |
| Travel and Lodging | $1,103.96 |
| Food and Beverage | $551.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,826.06 | 2025 | |
| Glaxosmithkline, LLC. | $680.07 | 2020-2024 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.94 | 2020-2023 | Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $199.79 | 2021-2023 | Fasenra, Breztri, Andexxa |
| Mylan Specialty L.P. | $94.19 | 2021-2023 | Yupelri |
| Electromed, INC. | $62.92 | 2021-2023 | Smartvest |
| Grifols USA, LLC | $24.34 | 2023 | Prolastin-C Liquid |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Inogen, INC. | $9.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinadh Annangi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.